Uncategorized
Midlife Brain Aging Linked to Immune Cell Remodeling, Blood-Brain Barrier Decline
Midlife Brain Aging Linked to Immune Cell Remodeling, Blood-Brain Barrier Decline
New data from a National Institutes of Health-funded study shows that midlife, the immune cell landscape of the hippocampus, undergoes substantial remodeling. It points to a potential mechanism by which aging may contribute to the chronic neuroinflammation commonly seen in neurodegenerative disease. Details are published in a new Science paper titled “Epigenetic and 3D genome reprogramming during the aging of human hippocampus.”
The work was done by a collaborative team of scientists from the University of California, San Diego, the New York Genome Center, and the University of California, Irvine. According to the paper, the scientists analyzed postmortem hippocampal tissue from 40 neurologically healthy adults aged 20 to 95 years old.
Digging into the details, the scientists used traditional measures of gene expression alongside more advanced techniques to analyze the genome’s 3D architecture and epigenome. “Gene expression tells us what a cell is doing today, but epigenetic signatures preserve information about where a cell came from,” said Nathan Zemke, PhD, director of single-cell genomics at the UC San Diego Center for Epigenomics and first author on the study. “By combining these approaches, we uncovered a major shift in the identity and lineage of immune cells in the aging human brain’s immune cells that gene expression data alone would not have revealed.”
They found that the brain’s primary immune cells progressively decline from age 50 to 75 years of age, and are replaced by cells with elevated inflammatory signatures and other features that resemble the characteristics of peripheral blood-derived immune cells. It raises questions as to whether microglia, which emerge during embryonic development, may not renew throughout the human lifespan as previously thought. The data also showed that cells that typically maintain the protective blood-brain barrier deteriorated with age. And across many brain cell types, aging accompanied a widespread and coordinated disruption of genome architecture.
“The progressive structural disruptions were closely linked to shifts in gene regulation and cell identity, potentially revealing a fundamental feature of aging in the human brain,” said Bing Ren, PhD, scientific director and CEO of the New York Genome Center, and professor of genetics and development at Columbia University. Ren is also a corresponding author on the study,
Future studies will investigate the mechanisms driving the loss of resident microglia and determine whether the newly identified immune-cell transition contributes directly to Alzheimer’s disease and other age-related neurological disorders. Insights from the current study as well as others could provide new opportunities to develop therapies that help to preserve brain function and reduce vulnerability to neurodegenerative disease.
The post Midlife Brain Aging Linked to Immune Cell Remodeling, Blood-Brain Barrier Decline appeared first on GEN – Genetic Engineering and Biotechnology News.
Uncategorized
Biologics push CMOs/CDMOs to expand sterile fill-finish and prefilled syringe capacity
Biologics push CMOs/CDMOs to expand sterile fill-finish and prefilled syringe capacity
As biologics, biosimilars and GLP-1s drive demand for sterile drug products, CMOs and CDMOs are investing in fill-finish, lyophilization, inspection and packaging capacity to keep pace with a dynamic injectable market. Read More
Uncategorized
Biotech leaders call for streamlining of INDs as FDA’s Trialblazer rolls out
The FDA’s new investigational new drug pilot program—one part of HHS’s broader clinical trial modernization initiatives—has lofty goals to expedite first-in-human trials of novel drugs, but experts say it won’t tip the scales much on its own.
Uncategorized
5 companies advancing ATTR assets in the wake of Wainua’s fail
The Phase 3 failure of AstraZeneca and Ionis Pharmaceuticals’ antisense therapy in transthyretin amyloid cardiomyopathy last month left the space reeling—and readjusting. BioSpace looks at five contenders and where they currently stand.
-
Fierce Biotech4 months ago
Scientists turn pig semen extract into eye drops that kill cancer in mice
-
Uncategorized9 years agoThese ’90s fashion trends are making a comeback in 2017
-
Endpoints News5 months ago
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
-
Uncategorized4 months agoNovartis buys Synnovation’s PI3Kα inhibitors for $3 billion
-
Uncategorized9 years agoAccording to Dior Couture, this taboo fashion accessory is back
-
Uncategorized9 years agoPhillies’ Aaron Altherr makes mind-boggling barehanded play
-
Uncategorized9 years agoSteph Curry finally got the contract he deserves from the Warriors
-
Uncategorized9 years agoUber and Lyft are finally available in all of New York State